Document:

Exhibit 10.4

 

CONFIDENTIAL

EXECUTION

 

REPURCHASE
AGREEMENT

 

This
REPURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 7, 2020, by and among Stable
Road Acquisition Corp., a Delaware corporation (“Parent”), Prime Movers Lab Fund I LP (the “Holder”)
and Momentus Inc., a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall
have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

 

WHEREAS,
as set forth in that certain Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”),
by and among Parent, Project Marvel First Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Parent
(“First Merger Sub”), Project Marvel Second Merger Sub, LLC a Delaware limited liability company and a direct,
wholly-owned subsidiary of Parent (“Second Merger Sub”) and the Company, amongst other things and in accordance
with the terms and subject to the conditions set forth therein (i) First Merger Sub will merge with and into the Company, with
the Company surviving as the Surviving Corporation (the “First Merger”), and (ii) immediately following the
First Merger and as part of the same overall transaction, the Surviving Corporation will merge with and into Second Merger Sub,
with Second Merger Sub surviving as the Surviving Entity (the “Second Merger”, together with the First Merger,
the “Mergers”);

 

WHEREAS,
the PIPE Investors have entered into Subscription Agreements with Parent, pursuant to which, among other things and on the terms
and subject to the conditions set forth in such Subscription Agreements, such PIPE Investors have agreed to purchase from Parent
shares of Parent’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), for
cash in an aggregate purchase price equal to the PIPE Investment Amount, with such purchases to be consummated immediately prior
to the closing under the Merger Agreement; and

 

WHEREAS,
Parent has agreed to repurchase a number of shares of Class A Common Stock from the Holder at a price of $10.00 per share, effective
as of immediately following the consummation of the Second Merger pursuant to the terms of the Merger Agreement (the “Second
Effective Time”), as further described below.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties
hereto hereby agree as follows:

 

1.
Repurchase.

 

(a)
Repurchase Shares. In accordance with the terms and subject to the conditions of this Agreement, following the Second Effective
Time, Parent hereby agrees to purchase from the Holder, and the Holder hereby agrees to sell to Parent (the “Repurchase”),
the number of shares of Class A Common Stock (such shares, the “Repurchase Shares”) equal to: (x) the Aggregate
Repurchase Price (defined below) divided by (y) $10.00, and rounded down to the nearest whole number of shares, as applicable.

 

     

     

    

 

(b)
Certain Definitions. For purposes of this Agreement:

 

(i)
“Net Proceeds” shall equal the amount equal to (I) Parent Cash at the Closing, minus (II) the sum of
(x) Parent Transaction Costs, (y) Company Transaction Costs and (z) amounts payable by Parent to Parent stockholders in connection
with the Parent Stockholder Redemptions; and

 

(ii)
“Aggregate Repurchase Price” shall equal:

 

(1)
If the Net Proceeds are greater than or equal to $280,000,000, $30,000,000;

 

(2)
If the Net Proceeds are less than $280,000,000 but greater than $265,000,000, (x) the Net Proceeds, minus (y) $250,000,000;
and

 

(3)
If the Net Proceeds are less than or equal to $265,000,000, $0. In such event, this Agreement shall automatically terminate and
become null and void and neither party shall have any obligations hereunder.

 

(iii)
“Holder Expense Amount” shall equal the amount equal to 3.3% of the Aggregate Repurchase Price.

 

2.
Qualifications. Notwithstanding anything to the contrary in this Agreement:

 

(a)
in no event will Parent be required to fund more than the Aggregate Repurchase Price, in each case, pursuant to Section 1
(it being understood that the Aggregate Purchase Price may be zero);

 

(b)
nothing in this Agreement shall limit or modify the rights or obligations of any party under the Merger Agreement; and

 

(c)
this Agreement will become effective upon, and only upon, the Closing (as defined in the Merger Agreement), and if the Closing
(as defined in the Merger Agreement) does not occur or the Merger Agreement is validly terminated for any reason, this Agreement
shall automatically terminate and become null and void and neither party shall have any obligations hereunder.

 

3.
Closing.

 

(a)
In accordance with the terms and subject to the conditions of this Agreement, the closing of the transaction contemplated by Section
1 (the “Closing”) shall take place promptly following the Second Effective Time. At the Closing:

 

(i)
Subject to the Aggregate Repurchase Price being greater than $0.00, Parent shall deliver (or cause to be delivered) to the Holder
an amount in cash, by wire transfer of immediately available funds to an account designated by the Holder in writing no later
than five (5) Business Days prior to the Closing, equal to (x) the Aggregate Repurchase Price, minus (y) the Holder Expense
Amount; and

 

    2

     

    

 

(ii)
the Holder shall deliver (or cause to be delivered):

 

(1)
the Repurchase Shares (along with any applicable instruments of transfer, including stock powers and letters of transmittal, as
applicable) in book entry form to Parent or to a custodian designated by Parent prior to the Closing;

 

(2)
a validly executed IRS Form W-9;

 

(3)
a completed copy of the Tax Certification Form attached hereto as Exhibit A; and

 

(4)
such documents or instruments required by the Company’s transfer agent.

 

(b)
The Closing shall be subject to the conditions that, on the Closing Date:

 

(i)
all of the conditions set forth in Article VIII of the Merger Agreement (including the condition set forth in Section 8.2(g) of
the Merger Agreement) shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied
at the Closing, but subject to the satisfaction or waiver thereof in accordance with the terms of the Merger Agreement), the Mergers
shall have been consummated and the Second Effective Time shall have occurred;

 

(ii)
Parent shall have received the PIPE Investment Amount; and

 

(iii)
(x) with respect to Parent, all representations and warranties of the Holder contained in this Agreement shall be true and correct
in all material respects as of the Closing Date (except with respect to such representations and warranties which speak as to
an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date,
except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Merger
Agreement), except for, in each case, inaccuracies in the representations and warranties of the Holder which would not preclude
the ability of the Holder to consummate the transactions contemplated hereby, and consummation of the Closing shall constitute
a reaffirmation by the Holder of each of the representations, warranties and agreements of the Holder contained in this Agreement
as of the Closing Date; and (y) with respect to the Holder, all representations and warranties of Parent contained in this Agreement
shall be true and correct in all material respects as of the Closing Date (except with respect to such representations and warranties
which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at
and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this
Agreement or the Merger Agreement), except for, in each case, inaccuracies in the representations and warranties of Parent which
would not preclude the ability of Parent to consummate Repurchase, and consummation of the Closing shall constitute a reaffirmation
by Parent of each of the representations, warranties and agreements of Parent contained in this Agreement as of the Closing Date.

 

(c)
At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional actions as the
parties reasonably may deem to be practical and necessary in order to consummate the transactions contemplated by this Agreement,
on the terms and conditions set forth herein.

 

    3

     

    

 

4.
Withholding. Parent, the Company and, following the Second Effective Time, the Surviving Entity, and each of their respective
agents, Affiliates and representatives, shall be entitled to deduct and withhold from any amount payable pursuant to this Agreement
any amounts as may be required to be deducted and withheld from such amounts under the Internal Revenue Code of 1986, as amended,
or any other applicable Law (as reasonably determined by Parent, the Company and, following the Second Effective Time, the Surviving
Entity, respectively). To the extent that any amounts are so deducted and withheld, such deducted and withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the person in respect of which such deduction and withholding
was made. In the event that withholding was required, to the extent that such amounts are not so deducted and withheld from any
Person, such Person shall indemnify Parent, the Company and, following the Second Effective Time, the Surviving Entity, and each
of their respective agents, Affiliates and representatives that was required to perform such withholding, for such amounts, together
with any related losses.

 

5.
The Holder acknowledges and agrees that the Holder Expense Amount shall represent the Holder’s obligation to pay the Company
a portion of the Company Transaction Costs, and Parent, the Holder and the Company each hereby agree that Parent can withhold
the Holder Expense Amount from the Aggregate Repurchase Price in full satisfaction and release of the Holder’s obligation
to pay the Company such portion of the Company Transaction Costs.

 

6.
Parent Representations and Warranties. Parent represents and warrants to the Holder that:

 

(a)
Due Incorporation, Authorization and Enforceability. Parent is duly incorporated and in good standing under the laws of
the State of Delaware. Subject to obtaining the approvals in connection with Parent’s performance of the Merger Agreement,
this Agreement and the transactions contemplated thereby and hereby (the “Required Approvals”), (i) Parent
has all requisite corporate power and authority to execute and deliver this Agreement and to consummate the Repurchase, (ii) this
Agreement has been duly authorized, executed and delivered by Parent, and (iii) assuming due authorization, execution and delivery
by, and enforceability against, the Holder, this Agreement constitutes the valid and binding obligation of Parent, enforceable
against Parent in accordance with its terms, subject to the Remedies Exception.

 

(b)
No Conflict. Subject to obtaining the Required Approvals, the execution and delivery by Parent of this Agreement and the
consummation by Parent of the Repurchase will not (i) conflict with Parent’s certificate of incorporation and bylaws, as
in effect at the time of such execution and delivery and the Repurchase, respectively, (ii) violate or conflict with any provision
of, or result in the breach of, or default under any applicable Law or governmental order applicable to Parent, or (iii) violate
or conflict with any provision of, or result in the breach of, result in the loss of any right or benefit, or cause acceleration,
or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation
or acceleration) under any contract, agreement or instrument (“Contract”) to which Parent is a party or by
which Parent may be bound, or terminate or result in the termination of any such Contract, except, in the case of clauses (ii)
and (iii), to the extent that the occurrence of the foregoing would not have, or would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of Parent to enter into and perform its obligations under this Agreement.

 

    4

     

    

 

(c)
No Consents. Subject to obtaining the Required Approvals, no consent, waiver, approval or authorization of, or designation,
declaration or filing with, or notification to, any Governmental Entity or other person is required on the part of Parent with
respect to Parent’s execution or delivery of this Agreement or the consummation of the Repurchase.

 

(d)
No Other Representations or Warranties. Parent acknowledges that there have been no representations, warranties, covenants
and agreements made to Parent by the Holder, expressly or by implication, other than those representations, warranties, covenants
and agreements included in this Agreement.

 

7.
Holder Representations and Warranties. The Holder represents and warrants to Parent that:

 

(a)
Authorization and Enforceability. The Holder is duly organized and in good standing as a limited partnership under the
laws of the State of Delaware and is treated as a partnership for applicable income tax purposes. The execution and delivery by
the Holder of this Agreement, the performance by the Holder of its obligations hereunder and the consummation by the Holder of
the transactions contemplated hereby, have been duly authorized by all requisite action on the part of the Holder. This Agreement
has been duly executed and delivered by the Holder, and (assuming due authorization, execution and delivery by, and enforceability
of this Agreement against, Parent) this Agreement constitutes a legal, valid and binding obligation of the Holder, enforceable
against the Holder in accordance with its terms, subject to the Remedies Exception.

 

(b)
No Conflict. The execution and delivery by the Holder of this Agreement, the performance by the Holder of its obligations
hereunder and the consummation by the Holder of the transactions contemplated hereby will not (i) conflict with the Holder’s
partnership agreement, certificate of limited partnership and other organizational documents, as in effect at the time of such
execution and delivery and the Repurchase, respectively, (ii) violate or conflict with any provision of, or result in the breach
of, or default under any applicable Law or governmental order applicable to the Holder, or (iii) violate or conflict with any
provision of, or result in the breach of, result in the loss of any right or benefit, or cause acceleration, or constitute (with
or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration)
under any Contract to which the Holder is a party or by which the Holder may be bound, or terminate or result in the termination
of any such Contract, except, in the case of clauses (ii) and (iii), to the extent that the occurrence of the foregoing would
not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability
of the Holder to enter into and perform its obligations under this Agreement.

 

(c)
No Consents. No consent, waiver, approval or authorization of, or designation, declaration or filing with, or notification
to, any Governmental Entity or other person is required on the part of the Holder with respect to the execution and delivery by
the Holder of this Agreement, the performance by the Holder of its obligations hereunder and the consummation by the Holder of
the transactions contemplated hereby.

 

    5

     

    

 

(d)
Ownership of Repurchase Shares. Immediately prior to the Closing, the Holder will own, beneficially and of record, and
will have valid title to, and the right to transfer to Parent, all of the Repurchase Shares to be sold by the Holder to Parent
pursuant to this Agreement, free and clear of any Lien of any kind or nature whatsoever. At the Closing, upon delivery from the
Holder of the Repurchase Shares in book entry form to Parent, in accordance with the terms of this Agreement, or to a custodian
designated by Parent prior to the Closing, and payment of the Repurchase Price for such Repurchase Shares, good and valid title
to such Repurchase Shares, free and clear of all Liens, will pass to Parent. No person has any written or oral agreement, arrangement
or understanding or option for, or any right or privilege (whether by Law, preemption or contract) that is or is capable of becoming
an agreement, arrangement or understanding or option for, the purchase or acquisition from the Holder of any of the Repurchase
Shares.

 

(e)
Information. The Holder acknowledges that it knows that Parent may have material, non-public information regarding Parent
and its condition (financial and otherwise), results of operations, businesses, properties, plans and prospects (collectively,
“Information”). The Holder acknowledges that it has been offered and does not wish to receive any of this Information
and that such Information might be material to the Holder’s decision to sell the Repurchase Shares or otherwise materially
adverse to the Holder’s interests. Accordingly, the Holder acknowledges and agrees that Parent shall not have any obligation
to disclose to the Holder any of such Information. The Holder, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the transactions contemplated
by this Agreement, including the Repurchase. The Holder hereby waives and releases, to the fullest extent permitted by applicable
Law, any and all claims and causes of action it has or may have against Parent and its Affiliates, controlling persons, officers,
directors, employees, representatives and agents, based upon, relating to or arising out of the Repurchase and the other transactions
contemplated hereby, including (without limitation) any claim or cause of action based upon, relating to or arising out of nondisclosure
of the Information.

 

(f)
No Other Representations or Warranties. The Holder acknowledges that there have been no representations, warranties, covenants
and agreements made to the Holder by Parent, or its officers or directors, expressly or by implication, other than those representations,
warranties, covenants and agreements included in this Agreement.

 

8.
Miscellaneous.

 

(a)
Notices. All notices and other communications among the parties shall be in writing and shall be deemed to have been duly
given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or
certified mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight
delivery service, or (iv) when delivered by email (provided no “bounceback” or notice of non-delivery is received),
addressed as follows:

 

if
to Parent, to:

 

	 	Stable
    Road Acquisition Corp.	 
	 	1345
    Abbott Kinney Boulevard	 
	 	Venice,
    CA 90291	 

	 	Attention:	Brian
    Kabot
	 	 	Juan
    Quiroga
	 	E-mail:	brian@stableroadcapital.com
	 	 	juan@nalainvestments.com

 

    6

     

    

 

with
a copy to (which shall not constitute notice):

 

	 	Kirkland
    & Ellis LLP	 
	 	300
    North LaSalle	 
	 	Chicago,
    IL 60654	 

	 	Attention:	Douglas
    C. Gessner, P.C.
	 	 	Bradley
    C. Reed, P.C.
	 	 	Kevin
    M. Frank
	 	E-mail:	douglas.gessner@kirkland.com
	 	 	bradley.reed@kirkland.com
	 	 	kevin.frank@kirkland.com

 

if
to the Holder, to:

 

	 	Prime
    Movers Lab LLC	 
	 	P.O.
    Box 12829	 
	 	Jackson,
    WY 83002	 

	 	Attention:	Daniel
    Narea
	 	E-mail:	daniel@primemoverslab.com

 

with
a copy to (which shall not constitute notice):

 

	 	Hogan
    Lovells US LLP	 
	 	3
    Embarcadero Center	 
	 	Suite
    1500	 
	 	San
    Francisco, CA 94111	 

	 	Attention:	Jon
    Layman
	 	E-mail:	jon.layman@hoganlovells.com

 

if
to the Company, to:

 

	 	Momentus
    Inc.	 
	 	3050
    Kenneth St.	 
	 	Santa
    Clara, CA 95054	 

	 	Attention:	Alexander
    Fishkin
	 	E-mail:	alex@momentus.space

 

    7

     

    

 

with
a copy to (which shall not constitute notice):

 

	 	Orrick,
    Herrington & Sutcliffe LLP	 
	 	631
    Wilshire Blvd, Suite 2-C	 
	 	Santa
    Monica, CA 90401	 

	 	Attention:	Daniel
    S. Kim
	 	 	Hari
    Raman
	 	 	Albert
    W. Vanderlaan
	 	E-mail:	dan.kim@orrick.com
	 	 	hraman@orrick.com
	 	 	avanderlaan@orrick.com

 

or
to such other address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside
counsel shall not constitute notice.

 

(b)
Headings; Counterparts. The headings in this Agreement are for convenience only and shall not be considered a part of or
affect the construction or interpretation of any provision of this Agreement. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

(c)
Expenses. Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and
disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

 

(d)
Entire Agreement; Third-Party Beneficiaries. This Agreement constitutes the entire agreement among the parties relating
to the transactions contemplated hereby and supersedes any other agreements, whether written or oral, that may have been made
or entered into by or among any of the parties hereto relating to the transactions contemplated hereby. Nothing expressed or implied
in this Agreement is intended or shall be construed to confer upon or give any Person, other than the parties hereto, any right
or remedies under or by reason of this Agreement.

 

(e)
Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction,
the other provisions of this Agreement shall remain in full force and effect. The parties further agree that if any provision
contained herein is, to any extent, held invalid or unenforceable in any respect under the laws governing this Agreement, they
shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent
permitted by Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained
herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the parties.

 

    8

     

    

 

(f)
Governing Law; Jurisdiction. This Agreement, and all claims or causes of action based upon, arising out of, or related
to this Agreement or the transactions contemplated hereby, shall be governed by, and construed in accordance with, the laws of
the State of Delaware, without giving effect to principles or rules of conflict of laws to the extent such principles or rules
would require or permit the application of laws of another jurisdiction. Any proceeding or action based upon, arising out of or
related to this Agreement or the transactions contemplated hereby must be brought in the Court of Chancery of the State of Delaware
(or, to the extent such Court does not have subject matter jurisdiction, the Superior Court of the State of Delaware), or, if
it has or can acquire jurisdiction, in the United States District Court for the District of Delaware, and each of the parties
irrevocably submits to the exclusive jurisdiction of each such court in any such proceeding or action, waives any objection it
may now or hereafter have to personal jurisdiction, venue or to convenience of forum, agrees that all claims in respect of the
proceeding or action shall be heard and determined only in any such court, and agrees not to bring any proceeding or action arising
out of or relating to this Agreement or the transactions contemplated hereby in any other court. Nothing herein contained shall
be deemed to affect the right of any party to serve process in any manner permitted by Law or to commence legal proceedings or
otherwise proceed against any other party in any other jurisdiction, in each case, to enforce judgments obtained in any action,
suit or proceeding brought pursuant to this Section 8(f).

 

(g)
Waiver of Jury Trial. Each party acknowledges and agrees that any controversy
which may arise under this Agreement and the transactions contemplated hereby is likely to involve complicated and difficult issues,
and therefore each such party hereby irrevocably, unconditionally and voluntarily waives any right such party may have to a trial
by jury in respect of any action, suit or proceeding directly or indirectly arising out of or relating to this Agreement or any
of the transactions contemplated hereby.

 

(h)
Assignment. No party hereto shall assign this Agreement or any part hereof without the prior written consent of the other
parties and any such transfer without prior written consent shall be void. Subject to the foregoing, this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

 

(i)
Publicity.

 

(i)
All press releases or other public communications relating to the transactions contemplated hereby, and the method of the release
for publication thereof, shall be subject to the prior mutual approval of Parent and the Holder, which approval shall not be unreasonably
withheld, conditioned or delayed; provided, however that no consent shall be required for any communications to a director, manager,
officer, stockholder, partner, limited partner, member, potential investor or affiliate of such entity or an investment fund or
other entity controlled or managed by such entity or any of its affiliates.

 

(ii)
The restriction in Section 8(i)(i) shall not apply to the extent the public announcement is required by applicable securities
law, any Governmental Entity or stock exchange rule; provided, however, that in such an event, the party making
the announcement shall use its commercially reasonable efforts to consult with the other parties in advance as to its form, content
and timing.

 

(j)
Amendment and Modification; Waiver. This Agreement may be amended or modified in whole or in part, only by a duly authorized
agreement in writing executed in the same manner as this Agreement and which makes reference to this Agreement. No waiver by any
party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving.
No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified
by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure
to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed
as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any
other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

    9

     

    

 

(k)
Enforcement. The parties hereto agree that irreparable damage could occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to seek specific
enforcement of the terms and provisions of this Agreement, in addition to any other remedy to which any party is entitled at law
or in equity. In the event that any action shall be brought in equity to enforce the provisions of this Agreement, no party shall
allege, and each party hereby waives the defense, that there is an adequate remedy at law, and each party agrees to waive any
requirement for the securing or posting of any bond in connection therewith.

 

(l)
Non-Recourse. This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of,
or related to this Agreement or the transactions contemplated hereby may only be brought against, the entities that are expressly
named as parties hereto and any express guarantor of any such party’s obligations hereunder and then only with respect to
the specific obligations set forth herein with respect to such party; provided, however, that the foregoing shall
not relieve any party for liability with respect to fraud.

 

(m)
Termination. This Agreement shall terminate and be void and of no further force and effect and all rights and obligations
of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest
to occur of (i) such date and time as the Merger Agreement is terminated in accordance with its terms, (ii) upon the mutual written
agreement of each of the parties hereto to terminate this Agreement, or (iii) if any of the conditions to Closing set forth in
Section 3(b) of this Agreement are not satisfied or waived, or are not capable of being satisfied, on or prior to the Closing
and, as a result thereof, the transactions contemplated by this Agreement will not be and are not consummated at the Closing;
provided, that nothing herein shall relieve any party from liability for any willful breach hereof prior to the time of
termination.

 

[SIGNATURE
PAGE FOLLOWS]

 

    10

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement or caused their duly authorized officers to execute this
Agreement as of the date first above written.

 

	 	STABLE ROAD ACQUISITION CORP.
	 	 	 
	 	By:	/s/
    Brian Kabot

	 	 	Name:	Brian
    Kabot
	 	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Repurchase Agreement]

 

    11

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement or caused their duly authorized officers to execute this
Agreement as of the date first above written.

 

	 	PRIME MOVERS LAB FUND I LP
	 	By: Prime Movers Lab GP I LLC
	 	Its: General Partner
	 	 	 	 
	 	By:	/s/ Dakin Sloss 
	 	 	Name:	Dakin
    Sloss
	 	 	Title:	Authorized
    Person

 

[Signature
Page to Repurchase Agreement]

 

    12

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement or caused their duly authorized officers to execute this
Agreement as of the date first above written.

 

	 	MOMENTUS INC.
	 	 	 	 
	 	By:	/s/ Mikhail Kokorich 
	 	 	Name:	Mikhail
    Kokorich
	 	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Repurchase Agreement]

 

    13

     

    

 

EXHIBIT
A

 

Tax
Certification – Stock Ownership

 

1.
Number of shares of Class A Common Stock received by the Holder in the First Merger: __________________________.

 

2.
Number of shares of Class A Common Stock owned by the Holder immediately following the Repurchase: __________________________.

 

Note:
For purposes of this Tax Certification, the number of shares of Class A Common Stock owned by the Holder shall include shares
it actually owns, and also shares it constructively owns within the meaning of section 318 of the Internal Revenue Code of 1986,
as amended.

 

The
undersigned declares and certifies that he or she has examined this certification and to the best of his or her knowledge and
belief it is true, correct, and complete. The undersigned further declares that he or she has the authority to sign this document
on behalf of Holder.

 

	 	PRIME MOVERS LAB FUND I LP
	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

 

14Exhibit 4.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES

 

COMMON
STOCK PURCHASE WARRANT

 

CANCER
GENETICS, INC.

 

	Warrant
    Shares: _______	Initial
    Exercise Date: November 2, 2020
	 	 
	 	Issue
    Date: November 2, 2020

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m.
(New York City time) on October 28, 2025 (the “Termination Date”) but not thereafter, to subscribe for and
purchase from Cancer Genetics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject
to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.

 

    	1

     

    

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed
to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential
employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of
any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
in The City of New York are generally are open for use by customers on such day.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

    	2

     

    

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing.

 

“Transfer
Agent” means Continental Stock Transfer & Trust Company, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30th Floor, New York, NY 10004 and a facsimile number of (212) 616-7613, and any successor
transfer agent of the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as
defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.

 

    	3

     

    

 

Without
limiting the rights of a Holder to receive Warrant Shares on a “cashless exercise” and without limiting the liquidated
damages provision in Section 2(d)(i) and the buy-in provision in Section 2(d)(iv), in no event will the Company be required to
net cash settle a Warrant exercise.

 

b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $2.42, subject to adjustment
hereunder (the “Exercise Price”).

 

c)
Cashless Exercise. If at any time after the six-month anniversary of the Issue Date, there is no effective registration
statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant
may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall
be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where

 

	 	(A) =	as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
    of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
    executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours”
    (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)
    at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
    of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the
    time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular
    trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after
    the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the
    date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
    is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such
    Trading Day;
	 	 	 
	 	(B) = 	the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X) =	the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless exercise.

 

    	4

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any
position contrary to this Section 2(c).

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise
by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee,
for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the
Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date,
the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for
all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading
Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the
Notice of Exercise.

 

    	5

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	6

     

    

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

    	7

     

    

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect
to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or,
upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

    	8

     

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	9

     

    

 

c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a
record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the
Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.

 

    	10

     

    

 

e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least five (5) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.

 

    	11

     

    

 

Section
4. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d)
hereof, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender
this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning
this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Initial Exercise Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does
not require registration under the Securities Act.

 

    	12

     

    

 

e)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

    	13

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	14

     

    

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally
recognized overnight courier service, addressed to the Company, at 201 Route 17 North, 2nd Floor, Rutherford, NJ 07070,
Attention: John A. Roberts, Chief Executive Officer, facsimile number: (201) 528-9201, email address: jay.roberts@cgix.com, or
such other facsimile number, email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the
facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice
or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by
the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any subsidiaries, the Company shall promptly file such notice with the
Commission pursuant to a Current Report on Form 8-K.

 

    	15

     

    

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holders of a majority in interest of the Warrants issued on this date then outstanding, on the other
hand.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	16

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	CANCER
    genetics, inc.
	 	 	 
	 	By:	                 
	 	Name:	 
	 	Title:	 

 

    	17

     

    

 

NOTICE
OF EXERCISE

 

To:
cancer genetics, inc.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

 

Name
of Authorized Signatory: ___________________________________________________________________

 

Title
of Authorized Signatory: ____________________________________________________________________

 

Date:
________________________________________________________________________________________

 

    	 

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)
	 	 
	Phone
    Number:	 
	 	 
	Email
    Address:	 
	 	 
	Dated:
    _______________ __, ______	 
	 	 
	Holder’s
    Signature:____________________________	 
	 	 
	Holder’s
    Address:_____________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]